Gastric Cancer Clinical Trial
Official title:
Helicobacter Pylori Genome Project (HpGP)
Verified date | December 2020 |
Source | National Cancer Institute (NCI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Helicobacter pylori is a common bacterial infection. It can lead to severe stomach problems, including stomach cancer. Researchers want to look at samples of the bacteria. These H. pylori strains will be taken from chronically infected people. They want to identify the genetic and epigenetic differences in H. pylori strains. This could help predict which people who get infected with the bacteria will get stomach cancer. This could lead to the cancer being detected earlier. It could also mean less people get stomach cancer. Objectives: To study genetic variations of H. pylori strains based on samples from chronically infected people. To identify the features of strains that might lead to severe stomach problems or stomach cancer. Eligibility: People ages 30-70 years who need an upper endoscopy or who were recently diagnosed with stomach cancer Design: Participants will be screened by the doctor who does their procedure and a study nurse. Participants who have endoscopy will have ~6 biopsies removed. These are tissue samples. They are about the size of a grain of rice. Participants will allow the study team to access reports from their stomach exam. Participants with stomach cancer will donate some of the tissue that will be removed during their clinical care. They will allow the study team to access reports of their surgery. They will also allow them to access the microscope slides of their stomach.
Status | Terminated |
Enrollment | 1000 |
Est. completion date | May 15, 2020 |
Est. primary completion date | May 15, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 30 Years to 70 Years |
Eligibility | INCLUSION CRITERIA: H. pylori strains collected from: 1. Adult aged 30 to 70 years old. 2. Patients who need upper endoscopy (examination of the lining of their stomach with a flexible tube). 3. Patients with stomach cancer. |
Country | Name | City | State |
---|---|---|---|
Algeria | Université Ferhat Abbas | Sétif | |
Argentina | Hospital Alemán | Buenos Aires | |
Bangladesh | Dhaka Medical College and Hospital | Dhaka | |
Belgium | Ghent University | Ghent | |
Brazil | Universidade Federal de Minas Gerais | Belo Horizonte | |
Brazil | AC Camargo Cancer Center | Sao Paulo | |
Bulgaria | Medical University of Sofia | Sofia | |
Bulgaria | Tsaritsa Yoanna University Hospital | Sofia | |
Cameroon | University of Dschang | Dschang | |
Canada | University of Alberta | Edmonton | |
Chile | Universidad de Concepción | Concepción | |
Chile | Hospital Hanga Roa | Easter Island | |
Chile | Pontificia Universidad Catolica | Santiago | |
Colombia | Instituto Nacional de Cancerología | Bogotá | |
Colombia | Universidad del Valle | Cali | |
Colombia | Universidad de Nariño | Pasto | |
Congo, The Democratic Republic of the | University of Kinshasa | Kinshasa | |
Congo, The Democratic Republic of the | University of Mbuji Mayi | Mbuji-Mayi | |
Costa Rica | Universidad de Costa Rica | San José | |
Dominican Republic | Universidad Autónoma de Santo Domingo | Santo Domingo | |
France | C.H.U. Pellegrin | Bordeaux | |
Germany | Otto-von-Guericke Universitätsklinikum | Magdeburg | |
Ghana | University of Cape Coast | Cape Coast | |
Greece | Evangelismos Hospital and Hellenic Pasteur Institute | Athens | |
Greece | Hellenic Pasteur Institute | Athens | |
Guatemala | Universidad San Carlos | Guatemala | |
Honduras | Hospital de Occidente | Santa Rosa De Copán | |
Iceland | National University Hospital | Reykjavík | |
India | Kasturba Medical College Manipal | Manipal | |
Indonesia | University of Indonesia | Kota Depok | |
Indonesia | Universitas Airlangga | Kota Surabaya | |
Iran, Islamic Republic of | Digestive Disease Research Institute | Teheran | |
Israel | Bar Ilan University | Ramat Gan | |
Italy | Centro di Rferimento Oncologico | Aviano | |
Japan | Nagoya City University | Nagoya | |
Japan | Oita University | Oita | |
Japan | HOSEI University | Tokyo | |
Japan | Kyorin University | Tokyo | |
Japan | Nippon Medical School | Tokyo | |
Jordan | Jordan University of Science and Technology | Ramtha | |
Kazakhstan | Central Asian Cancer Institute | Almaty | |
Kenya | Tenwek Hospital | Bomet | |
Korea, Republic of | Seoul National University Bundang Hospital | Seongnam | |
Korea, Republic of | Chung-Ang University Hospital | Seoul | |
Korea, Republic of | National Cancer Center | Seoul | |
Kyrgyzstan | Kyrgyz State Medical Academy | Bishkek | |
Latvia | University of Latvia | Riga | |
Lithuania | Lithuanian University of Health Sciences | Kaunas | |
Malaysia | University of Malaya | Kuala Lumpur | |
Mexico | Instituto Nacional de Cancerología | Mexico City | |
Myanmar | Defence Services General Hospital | Yangon | |
Nepal | Chitwan Medical College | Bharatpur | |
Nepal | Tribhuvan University Teaching Hospital | Kathmandu | |
Nigeria | University of Calabar Teaching Hospital | Calabar | |
Nigeria | University of Nigeria Teaching Hospital | Enugu | |
Nigeria | Babcock Universtiy Teaching Hospital | Ilishan-Remo | |
Nigeria | University of Jos / University Teaching Hospital | Jos | |
Nigeria | Federal Medical Center | Lagos | |
Peru | Instituto Nacional de Enfermedades Neoplasicas | Lima | |
Peru | Universidad Peruana Cayetano Heredia | Lima | |
Poland | University of Lublin | Publin | |
Poland | Wroclaw Medical Center | Wroclaw | |
Portugal | Instituto Nacional de Saúde Dr. Ricardo Jorge | Lisbon | |
Portugal | University of Porto | Porto | |
Puerto Rico | University of Puerto Rico | San Juan | |
Russian Federation | Clinical Research Center of Moscow | Moscow | |
Singapore | National University Hospital | Singapore | |
South Africa | Chris Hani Baragwanath Academic Hospital | Soweto | |
Spain | Hospital Clinic de Barcelona | Barcelona | |
Spain | Hospital General de Granollers | Barcelona | |
Spain | Hospital Universitari Parc Tauli | Barcelona | |
Spain | Institut d'Investigació Biomédica de Bellvitge (Idibell) | Barcelona | |
Spain | L'Hospitalet de Llobregat | Barcelona | |
Spain | Hospital de Leon | León | |
Spain | Hospital de la Princesa | Madrid | |
Spain | Hospital General Universitario Gregorio Marañón | Madrid | |
Spain | Hospital Universitario de Asturias | Oviedo | |
Spain | Complejo Hospitalario de Navarra | Pamplona | |
Spain | Hospital Donostia | San Sebastian | |
Spain | Lozano Blesa University Hospital | Zaragoza | |
Sudan | Sudan University of Science and Technology | Khartoum | |
Sweden | Karolinska Institutet | Stockholm | |
Switzerland | University of Bern | Bern | |
Switzerland | University of Zurich | Zurich | |
Taiwan | National Taiwan University Hospital | Taipei | |
Turkey | Istanbul University | Istanbul | |
United States | Georgia Cancer Center Biorepository | Athens | Georgia |
United States | Centers for Disease Control and Prevention | Atlanta | Georgia |
United States | White River Medical Center | Batesville | Arkansas |
United States | Albert Einstein College of Medicine | Bronx | New York |
United States | Baylor College of Medicine | Houston | Texas |
United States | Vanderbilt University Medical Center | Nashville | Tennessee |
United States | Stanford University | Stanford | California |
Vietnam | Cho Ray Hospital | Ho Chi Minh City |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) | Chiba University, Japan, HOSEI University, Japan, Instituto de Biomedicina de Valencia, Spain, Instituto Mexicano de Seguro Social, Mexico, Karolinska Institutet, Max von Pettenkofer-Institute of Hygiene and Medical Microbiology, Germany, National Institute for Basic Biology, Japan, National Institute of Genetics, Japan, National Institute of Infectious Diseases, Japan, New England Biolabs, USA, Universidad de Chile, Chile, Universidade de Lisboa, Portugal, University of Bath, UK, University of Tokyo, Japan, Vanderbilt University Medical Center, USA |
United States, Vietnam, Algeria, Argentina, Bangladesh, Belgium, Brazil, Bulgaria, Cameroon, Canada, Chile, Colombia, Congo, The Democratic Republic of the, Costa Rica, Dominican Republic, France, Germany, Ghana, Greece, Guatemala, Honduras, Iceland, India, Indonesia, Iran, Islamic Republic of, Israel, Italy, Japan, Jordan, Kazakhstan, Kenya, Korea, Republic of, Kyrgyzstan, Latvia, Lithuania, Malaysia, Mexico, Myanmar, Nepal, Nigeria, Peru, Poland, Portugal, Puerto Rico, Russian Federation, Singapore, South Africa, Spain, Sudan, Sweden, Switzerland, Taiwan, Turkey,
Correa P, Haenszel W, Cuello C, Tannenbaum S, Archer M. A model for gastric cancer epidemiology. Lancet. 1975 Jul 12;2(7924):58-60. — View Citation
Krebes J, Morgan RD, Bunk B, Spröer C, Luong K, Parusel R, Anton BP, König C, Josenhans C, Overmann J, Roberts RJ, Korlach J, Suerbaum S. The complex methylome of the human gastric pathogen Helicobacter pylori. Nucleic Acids Res. 2014 Feb;42(4):2415-32. doi: 10.1093/nar/gkt1201. Epub 2013 Dec 2. — View Citation
Tomb JF, White O, Kerlavage AR, Clayton RA, Sutton GG, Fleischmann RD, Ketchum KA, Klenk HP, Gill S, Dougherty BA, Nelson K, Quackenbush J, Zhou L, Kirkness EF, Peterson S, Loftus B, Richardson D, Dodson R, Khalak HG, Glodek A, McKenney K, Fitzegerald LM, Lee N, Adams MD, Hickey EK, Berg DE, Gocayne JD, Utterback TR, Peterson JD, Kelley JM, Cotton MD, Weidman JM, Fujii C, Bowman C, Watthey L, Wallin E, Hayes WS, Borodovsky M, Karp PD, Smith HO, Fraser CM, Venter JC. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature. 1997 Aug 7;388(6642):539-47. Erratum in: Nature 1997 Sep 25;389(6649):412. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Bacterial DNA sequence | genome and methylome | At enrollment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05551416 -
The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
|
||
Completed |
NCT05518929 -
Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients
|
Phase 4 | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03219593 -
Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Recruiting |
NCT05536102 -
The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Active, not recruiting |
NCT04082364 -
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
|
Phase 2/Phase 3 | |
Withdrawn |
NCT03766607 -
Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT01924533 -
Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.
|
Phase 3 | |
Terminated |
NCT01641939 -
A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT04908813 -
Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04249739 -
Pembrolizumab + Capecitabine/Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive
|
Phase 2 | |
Recruiting |
NCT05514158 -
To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)
|
Phase 1 | |
Recruiting |
NCT04931654 -
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 |